Across 3 studies, 1 reported a beneficial small-sized effect on reducing blood cholesterol, while 2 found no significant effect. The median study duration was 70 days, suggesting effects may be observed within 8–12 weeks, though the evidence base is too limited to draw firm conclusions. The most-studied dose was approximately 600–1800 mg/day of EPA+DHA, primarily in clinical populations (MASLD, migraine, MDD).

• Effective dose range: 600–1800 mg/day EPA+DHA
• Studied populations: clinical populations (metabolic dysfunction-associated steatotic liver disease, migraine, major depressive disorder)

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. The only significant beneficial result came from a very small RCT (n=47), and the largest study (n=439, meta-analysis) showed a trend toward benefit that did not reach statistical significance.